阿仑单抗诱发Graves病的患病率、危险因素及临床和生化特征
该回顾性随访研究纳入2014至2020年挪威4家医院接受阿仑单抗治疗的183例多发性硬化患者,75例(41%)出现甲状腺功能障碍,其中58例(77%)为Graves病。Graves病以交替性甲亢与甲减为特征,缓解率和甲状腺眼病患病率均低于传统Graves病,妊娠均无并发症,且Graves病与后续多发性硬化活动风险较低相关。
要点
- 阿仑单抗治疗的多发性硬化患者中41%出现甲状腺功能障碍,其中77%为Graves病。
- Graves病患者中41%呈交替性甲亢与甲减,40%促甲状腺素受体抗体转阴并停药。
- 甲状腺眼病患病率16%,妊娠均无母胎并发症,Graves病与较低的多发性硬化活动相关。
核心结论
- Graves病是阿仑单抗治疗非常常见的并发症,以交替性甲亢与甲减为特征。
- 其缓解率和甲状腺眼病患病率均低于传统Graves病报道的水平。
- 妊娠均无并发症,且Graves病与后续多发性硬化活动风险较低相关。
研究设计与样本
- 回顾性随访研究,纳入2014至2020年挪威4家医院接受阿仑单抗治疗的多发性硬化患者,203例中入组183例(90%,女性68%)。
主要发现
- 183例中75例(41%)发生甲状腺功能障碍,其中58例(77%)为Graves病。
- 从首次阿仑单抗剂量至Graves病诊断的中位时间为25个月(范围0-64)。
- 58例Graves病患者中24例(41%)出现交替性甲亢与甲减。
- 58例中23例(40%)促甲状腺素受体抗体转阴,在中位22个月(范围2-58)后停用抗甲状腺药物;26例(44%)在中位39个月(范围11-72)随访期间疾病活动。
- 2例(3%)接受放射性碘根治治疗,6例(10%)接受甲状腺切除术;9例(16%)发生甲状腺眼病,其中7例轻度、2例中重度;4例完成妊娠,均无母胎并发症。
关键数值与推荐
- 发生Graves病的患者新发多发性硬化复发和MRI病灶的频率低于未发生Graves病者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Atypical Graves disease (GD) is a common complication in multiple sclerosis (MS) patients treated with alemtuzumab. We present epidemiological, clinical, and biochemical characteristics of alemtuzumab-induced GD. METHODS: Retrospective follow-up study of MS patients treated with alemtuzumab from 2014 to 2020, including clinical course of GD, pregnancy outcome, and thyroid eye disease (TED). RESULTS: We enrolled 183 of 203 patients (90%, 68% women) treated with alemtuzumab at 4 hospitals in Norway. Seventy-five (41%) developed thyroid dysfunction, of whom 58 (77%) had GD. Median time from the first dose of alemtuzumab to GD diagnosis was 25 months (range, 0-64). Twenty-four of 58 GD patients (41%) had alternating phases of hyper- and hypothyroidism. Thyrotropin receptor antibodies became undetectable in 23 of 58 (40%) and they could discontinue antithyroid drug treatment after a median of 22 (range, 2-58) months. Conversely, 26 (44%) had active disease during a median follow-up of 39 months (range, 11-72). Two patients (3%) received definitive treatment with radioiodine, 6 (10%) with thyroidectomy. Nine developed TED (16%), 7 had mild and 2 moderate to severe disease. Four patients completed pregnancy, all without maternal or fetal complications. Patients who developed GD had a lower frequency of new MS relapses and MRI lesions than those without. CONCLUSION: GD is a very common complication of alemtuzumab treatment and is characterized by alternating hyper- and hypothyroidism. Both remission rates and the prevalence of TED were lower than those reported for conventional GD. Pregnancies were uncomplicated and GD was associated with a lower risk of subsequent MS activity.
引用
- Ueland GÅ, Ueland HO, Stokland AM, et al. Prevalence, Risk Factors, and Clinical and Biochemical Characteristics of Alemtuzumab-Induced Graves Disease. J Clin Endocrinol Metab. 2024. PMID: 37708353. doi:10.1210/clinem/dgad540
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。